Nektar Therapeutics, a San Francisco-based biopharmaceutical company with 137 employees, focuses on developing immunotherapy medicines for oncology and immunology, including NKTR-255 and Rezpegaldesleukin. Its pipeline targets immune response pathways to address cancer and autoimmune conditions.